• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 6-K filed by Satellos Bioscience Inc.

    4/9/26 7:00:08 AM ET
    $MSLE
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $MSLE alert in real time by email
    6-K 1 f6k_040826.htm FORM 6-K
     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Form 6-K

    REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

    For the month of April 2026

    Commission File Number: 001-43107

    SATELLOS BIOSCIENCE INC.
    (Translation of registrant's name into English)

    Royal Bank Plaza, South Tower, 200 Bay Street, Suite 2800
    Toronto, Ontario, ON M5J 2J3

    (Address of principal executive office)

    Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
    Form 20-F [   ]      Form 40-F [ X ]

     

     


    DOCUMENTS INCLUDED AS PART OF THIS FORM 6-K

     

    Exhibit Description
       
    99.1 Satellos to Present at the Bloom Burton & Co. Healthcare Investor Conference

    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

          SATELLOS BIOSCIENCE INC.    
      (Registrant)
       
      
    Date: April 9, 2026     /s/ Elizabeth Williams, CPA, CA    
      Elizabeth Williams, CPA, CA
      Chief Financial Officer
      
    Get the next $MSLE alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $MSLE

    DatePrice TargetRatingAnalyst
    4/6/2026$20.00Outperform
    Leerink Partners
    3/11/2026Overweight
    Cantor Fitzgerald
    More analyst ratings

    $MSLE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Leerink Partners initiated coverage on Satellos Bioscience with a new price target

    Leerink Partners initiated coverage of Satellos Bioscience with a rating of Outperform and set a new price target of $20.00

    4/6/26 8:45:33 AM ET
    $MSLE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cantor Fitzgerald initiated coverage on Satellos Bioscience

    Cantor Fitzgerald initiated coverage of Satellos Bioscience with a rating of Overweight

    3/11/26 8:39:55 AM ET
    $MSLE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MSLE
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Satellos to Present at the Bloom Burton & Co. Healthcare Investor Conference

    TORONTO, April 09, 2026 (GLOBE NEWSWIRE) -- Satellos Bioscience Inc. (NASDAQ:MSLE, TSX:MSCL) (" Satellos " or the " Company "), a clinical-stage biotechnology company developing life-improving medicines to treat degenerative muscle diseases, today announced that it will participate in the Bloom Burton & Co. Healthcare Investor Conference taking place April 21-22, 2026, at the Metro Toronto Convention Centre in Toronto, Canada. Satellos Co-founder and CEO Frank Gleeson will provide a presentation on April 21 and along with Liz Williams, Chief Financial Officer, will participate in one-on-one meetings during the conference. 2026 Bloom Burton & Co. Healthcare Investor ConferenceFormat: Pres

    4/9/26 7:00:00 AM ET
    $MSLE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Satellos Reports 2025 Financial Results and Highlights Recent Company Progress

    Completed a US$57.2 million equity financing; commenced trading on the Nasdaq Global Market under the ticker "MSLE" on Feb. 6, 2026 Secured global regulatory clearances and initiated BASECAMP, a placebo-controlled Phase 2 clinical trial of SAT-3247 in boys aged 7 to less than 10 years living with Duchenne muscular dystrophy ("Duchenne" or "DMD") Presented initial functional outcomes from 56 days of treatment in TRAILHEAD (follow-on trial to CL-101) at the 2026 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference, demonstrating that grip strength improvements observed in CL-101 were maintained or improved in TRAILHEAD over an aggregate period of 9 to 13 months Reported pro

    3/27/26 7:00:00 AM ET
    $MSLE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Satellos Presents Interim SAT-3247 Clinical and Biomarker Data in Duchenne Muscular Dystrophy at the 2026 MDA Clinical & Scientific Conference

    Interim observations from the Phase 2 TRAILHEAD study show continued improvement in handgrip strength, overall stability of elbow and shoulder strength in new dynamometry measurements Greater improvements in strength observed in participants with greater baseline muscle mass, further supporting evaluation in younger ages in ongoing BASECAMP studyProteomic analysis from the CL-101, 28-day Phase 1a/b study demonstrated reduction in established DMD biomarkers within two weeks of SAT-3247 administrationPreclinical data in facioscapulohumeral muscular dystrophy (FSHD) show enhanced muscle strength, supporting broader clinical potential of SAT-3247Enrollment ongoing in TRAILHEAD and BASECAMP

    3/10/26 7:00:00 AM ET
    $MSLE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MSLE
    SEC Filings

    View All

    SEC Form 6-K filed by Satellos Bioscience Inc.

    6-K - Satellos Bioscience Inc. (0001421642) (Filer)

    4/9/26 7:00:08 AM ET
    $MSLE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form S-8 filed by Satellos Bioscience Inc.

    S-8 - Satellos Bioscience Inc. (0001421642) (Filer)

    3/27/26 8:36:06 AM ET
    $MSLE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 40-F filed by Satellos Bioscience Inc.

    40-F - Satellos Bioscience Inc. (0001421642) (Filer)

    3/27/26 8:24:22 AM ET
    $MSLE
    Biotechnology: Pharmaceutical Preparations
    Health Care